NFATC2 and glioma: Although further experimental validation is needed to elucidate whether sorafenib or other drugs modulate TRAF3IP3‐mediated immune resistance via ERK/NFATC2/PD‐L1 signaling, the result once again confirms the reliability of our drug screening process based on the IGLoS score and the potential of TRAF3IP3 in glioma‐targeted therapies.